Agger Mette Kirstine
SEC insider (Form 3/4/5 filer). CIK 0001722234. Director at Lexeo Therapeutics, Inc. (LXEO) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 25, 2026. Located in NEW YORK, NY.
Companies Agger Mette Kirstine has filed insider reports for
- Lexeo Therapeutics, Inc. (LXEO): Director
- scPharmaceuticals Inc. (SCPH): Director
Agger Mette Kirstine
CIK: 0001722234
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 25, 2026LXEO
Lexeo Therapeutics, Inc.
AwardDirectStock Option (right to buy)
35K shares- - Oct 7, 2025SCPH
scPharmaceuticals Inc.
DispositionDirectStock Option (Right to Buy)
30K shares- - Oct 7, 2025SCPH
scPharmaceuticals Inc.
DispositionDirectStock Option (Right to Buy)
19.8K shares- - Jun 26, 2025LXEO
Lexeo Therapeutics, Inc.
AwardDirectStock Option (right to buy)
25K shares- - Jun 3, 2025SCPH
scPharmaceuticals Inc.
AwardDirectStock Option (Right to Buy)
30K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 25, 2026 |  LXEO Lexeo Therapeutics, Inc. | Award Stock Option (right to buy) | 35,000 | - | - | Direct |
| Oct 7, 2025 |  SCPH scPharmaceuticals Inc. | Disposition Stock Option (Right to Buy) | 30,000 | - | - | Direct |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | Disposition Stock Option (Right to Buy) | 19,750 | - | - | Direct |
| Jun 26, 2025 | LXEO Lexeo Therapeutics, Inc. | Award Stock Option (right to buy) | 25,000 | - | - | Direct |
| Jun 3, 2025 | SCPH scPharmaceuticals Inc. | Award Stock Option (Right to Buy) | 30,000 | - | - | Direct |
1-5 of 5 transactions